CHERISH HANNAH: Open Payments
NPI 1336809649 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,513 in 170 payments from 20 companies in 2025. Trend: 2023 $3,253 · 2024 $1,828 · 2025 $3,513
Food & beverage: $3,493Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $835 |
| Madrigal Pharmaceuticals | 18 | $706 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $345 |
| Janssen Biotech, Inc. | 11 | $257 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $240 |
| Celltrion USA Inc. | 20 | $167 |
| Lilly USA, LLC | 6 | $154 |
| PFIZER INC. | 8 | $152 |
| GENZYME CORPORATION | 6 | $148 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
Products named: REZDIFFRA, ENTYVIO, DUPIXENT, TREMFYA, RINVOQ, SKYRIZI, XIFAXAN, LINZESS.
Industry payments across MD — which companies pay providers there.
